{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:51:48Z","timestamp":1767847908690,"version":"3.49.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.gastrohep.2014.12.003","type":"journal-article","created":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T04:45:48Z","timestamp":1421988348000},"page":"338-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Vedolizumab en el tratamiento de la enfermedad de Crohn"],"prefix":"10.1016","volume":"38","author":[{"given":"Javier P.","family":"Gisbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugeni","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2014.12.003_bib0335","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0210-5705(02)70275-6","article-title":"Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease","volume":"25","author":"Gisbert","year":"2002","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0340","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0345","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/MEG.0b013e3283556db5","article-title":"Methotrexate in inflammatory bowel disease: A multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience","volume":"24","author":"Gonzalez-Lama","year":"2012","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0655","article-title":"Reccomendations of the Spanish Working Group on Crohn's disease and ulcerative colitis (GETECCU) on the use of methotrexate in inflammatory bowel diseases","author":"Gomollon","year":"2014","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0355","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MCG.0b013e31802e6875","article-title":"Long-term methotrexate for Crohn's disease: Safety and efficacy in clinical practice","volume":"42","author":"Domenech","year":"2008","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0360","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.gastrohep.2013.01.002","article-title":"Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease","volume":"36","author":"Cabriada","year":"2013","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0365","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: Loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.trsl.2014.01.002","article-title":"Biologic therapies in inflammatory bowel disease","author":"Cohen","year":"2014","journal-title":"Transl Res."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0665","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0380","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.crohns.2011.07.005","article-title":"Intensification of infliximab therapy in Crohn's disease: Efficacy and safety","volume":"6","author":"Chaparro","year":"2012","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0385","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MCG.0b013e3181ebaef9","article-title":"Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose escalation in patients losing response","volume":"45","author":"Chaparro","year":"2011","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0390","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ajg.2009.59","article-title":"Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial","volume":"104","author":"Colombel","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0395","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0400","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0405","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3748\/wjg.v20.i5.1139","article-title":"When combination therapy isn\u2019t working: Emerging therapies for the management of inflammatory bowel disease","volume":"20","author":"Krishnareddy","year":"2014","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0410","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MOG.0b013e3283622914","article-title":"Moving towards disease modification in inflammatory bowel disease therapy","volume":"29","author":"Allen","year":"2013","journal-title":"Curr Opin Gastroenterol."},{"issue":"Suppl 2","key":"10.1016\/j.gastrohep.2014.12.003_bib0415","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0210-5705(13)70050-5","article-title":"New advances in the treatment of inflammatory bowel disease","volume":"36","author":"Chaparro","year":"2013","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0420","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11894-012-0311-3","article-title":"Novel targets for inflammatory bowel disease therapeutics","volume":"15","author":"Lowenberg","year":"2013","journal-title":"Curr Gastroenterol Rep."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0425","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14712598.2014.885945","article-title":"New biologic therapeutics for ulcerative colitis and Crohn's disease","volume":"14","author":"Mozaffari","year":"2014","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0430","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1756283X09356872","article-title":"Current directions of biologic therapies in inflammatory bowel disease","volume":"3","author":"Reenaers","year":"2010","journal-title":"Therap Adv Gastroenterol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0435","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/1751-2980.12048","article-title":"Recent developments in the treatment of inflammatory bowel disease","volume":"14","author":"Rietdijk","year":"2013","journal-title":"J Dig Dis."},{"issue":"Suppl 3","key":"10.1016\/j.gastrohep.2014.12.003_bib0440","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000342742","article-title":"The future of inflammatory bowel disease therapy: Where do we go from here?","volume":"30","author":"Sandborn","year":"2012","journal-title":"Dig Dis."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0445","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMe1307415","article-title":"Inhibition of leukocyte trafficking in inflammatory bowel disease","volume":"369","author":"Cominelli","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0450","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/eci.10.40","article-title":"Leukocyte traffic control: A novel therapeutic strategy for inflammatory bowel disease","volume":"6","author":"Fiorino","year":"2010","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0455","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/08830185.2012.690794","article-title":"Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease","volume":"31","author":"Ghosh","year":"2012","journal-title":"Int Rev Immunol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0460","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: Anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobaton","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0465","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2217\/imt.12.85","article-title":"Vedolizumab for the treatment of ulcerative colitis and Crohn's disease","volume":"4","author":"McLean","year":"2012","journal-title":"Immunotherapy."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0470","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40265-013-0176-2","article-title":"T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: Current and future prospects","volume":"74","author":"Mosli","year":"2014","journal-title":"Drugs."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-011-0104-6","article-title":"Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis","volume":"20","author":"Thomas","year":"2012","journal-title":"Inflammopharmacology."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0480","first-page":"1295","article-title":"Vedolizumab, a humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn's disease","volume":"11","author":"Tilg","year":"2010","journal-title":"Curr Opin Investig Drugs."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0485","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1136\/gutjnl-2013-305967","article-title":"alpha4beta7 integrin: Beyond T cell trafficking","volume":"63","author":"Kempster","year":"2014","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0670","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0490","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0495","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0500","first-page":"179","article-title":"Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases","volume":"27","author":"Rezaie","year":"2014","journal-title":"Ann Gastroenterol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0505","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4161\/mabs.26392","article-title":"In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes","volume":"5","author":"Wyant","year":"2013","journal-title":"MAbs."},{"issue":"3-4","key":"10.1016\/j.gastrohep.2014.12.003_bib0510","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000354687","article-title":"B lymphocytes in inflammatory bowel diseases: Lessons from clinical trials","volume":"31","author":"Gerner","year":"2013","journal-title":"Dig Dis."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0515","doi-asserted-by":"crossref","DOI":"10.1517\/14712598.2014.880109","article-title":"Therapeutic peptides in inflammatory bowel disease","author":"Herrlinger","year":"2014","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0520","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s40265-014-0253-1","article-title":"Vedolizumab: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs."},{"issue":"suppl.1","key":"10.1016\/j.gastrohep.2014.12.003_bib0525","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/S1873-9946(14)60505-5","article-title":"Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's disease","volume":"8","author":"Rosario","year":"2014","journal-title":"J Crohns Colitis."},{"issue":"1-2","key":"10.1016\/j.gastrohep.2014.12.003_bib0530","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.08.011","article-title":"Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype","volume":"264","author":"Milch","year":"2013","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0535","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(14)62140-5","article-title":"Population pharmacokinetic modeling of vedolizumab in patients with ulcerative colitis or Crohn's disease","volume":"146","author":"Dirks","year":"2014","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0540","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ibd.21896","article-title":"Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study","volume":"18","author":"Parikh","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0545","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2174\/13894501113146660206","article-title":"Vedolizumab for the treatment of IBD: A selective therapeutic approach targeting pathogenic a4b7 cells","volume":"14","author":"Jovani","year":"2013","journal-title":"Curr Drug Targets."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0550","first-page":"A","article-title":"The effect of \u03b14\u03b27 blockade on lymphocyte trafficking in the acute injury colitis model","volume":"136","author":"Wang","year":"2009","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0555","unstructured":"Vedolizumab Ficha t\u00e9cnica. [consultado 15 Oct 2014]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/002782\/WC500168528.pdf"},{"issue":"S1","key":"10.1016\/j.gastrohep.2014.12.003_bib0560","first-page":"A67","article-title":"Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease","volume":"2","author":"Sands","year":"2014","journal-title":"United European Gastroenterology Journal"},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0565","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0570","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0575","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/MIB.0b013e318281f538","article-title":"Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease","volume":"19","author":"Parikh","year":"2013","journal-title":"Inflamm Bowel Dis."},{"issue":"1S","key":"10.1016\/j.gastrohep.2014.12.003_bib0580","first-page":"A66","article-title":"Long-term efficacy of vedolizumab therapy for Crohn's disease","volume":"2","author":"Hanauer","year":"2014","journal-title":"United European Gastroenterology Journal"},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0585","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(13)62854-1","article-title":"Efficacy of vedolizumab in Crohn's disease by prior treatment failure in Gemini II, a randomized, placebo-controlled, double-blind, multicenter study","volume":"144","author":"Hanauer","year":"2013","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0590","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(14)62132-6","article-title":"Effects of continued vedolizumab therapy for Crohn's disease in week 6 induction therapy nonresponders","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology."},{"issue":"I (suppl.1)","key":"10.1016\/j.gastrohep.2014.12.003_bib0595","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/S1873-9946(14)60617-6","article-title":"Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6","volume":"8","author":"Sandborn","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0600","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0605","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(13)60410-2","article-title":"Integrated safety analysis of vedolizumab for the treatment of ulcerative colitis or Crohn's disease","volume":"144","author":"Colombel","year":"2013","journal-title":"Gastroenterology."},{"issue":"Suppl.1","key":"10.1016\/j.gastrohep.2014.12.003_bib0610","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.14309\/00000434-201310001-01674","article-title":"Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn's disease","volume":"108","author":"Colombel","year":"2013","journal-title":"Am J Gastroenterol."},{"issue":"1S","key":"10.1016\/j.gastrohep.2014.12.003_bib0615","first-page":"A82","article-title":"Safety of vedolizumab alone or with concomitant corticosteroids and\/or immunosuppressants in patients with ulcerative colitis or Crohn's disease","volume":"2","author":"Colombel","year":"2014","journal-title":"United European Gastroenterology Journal"},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0620","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2013.141","article-title":"Anti-adhesion therapies and the rule of 3 for rare events","volume":"108","author":"Govani","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0625","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.4049\/jimmunol.1202490","article-title":"Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis","volume":"190","author":"Haanstra","year":"2013","journal-title":"J Immunol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0630","first-page":"1131","article-title":"Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis","volume":"6","author":"Herold","year":"2012","journal-title":"Clin Ophthalmol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0675","first-page":"1","article-title":"Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patients","author":"Cordioli","year":"2014","journal-title":"Neurol Sci."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0640","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1873-9946(09)60157-4","article-title":"Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to \u03b1 4\u03b2 7 integrin","volume":"3","author":"Parikh","year":"2009","journal-title":"J Crohn Colitis."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0645","first-page":"S1","article-title":"The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates","volume":"5","author":"Fedyk","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0650","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0680","doi-asserted-by":"crossref","DOI":"10.1111\/apt.13083","article-title":"Systematic review with Meta-analysis: the efcacy of a second anti-TNF in patients with inammatory bowel disease whose previous anti-TNF treatment has failed","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2014.12.003_bib0685","doi-asserted-by":"crossref","DOI":"10.3109\/00365521.2014.928901","article-title":"Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?","author":"Gisbert","year":"2015","journal-title":"Scand J Gastroenterol."}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570514003215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570514003215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T07:25:22Z","timestamp":1598685922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570514003215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0210570514003215"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2014.12.003","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vedolizumab en el tratamiento de la enfermedad de Crohn","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2014.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. and AEEH y AEG. All rights reserved.","name":"copyright","label":"Copyright"}]}}